Re: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
نویسندگان
چکیده
Recent clinical data (1) suggest that c-erbB-2 overexpression/amplification might be associated with tamoxifen resistance in patients with estrogen receptor (ER)-positive tumors. This association is controversial, however, and the question of the efficacy of hormone therapy in these patients is still a matter of debate. In a recent issue of the Journal, Konecny et al. (2) provided some answers to this question. After considering c-erbB-2, ER, and progesterone receptors (PRs) as continuous variables, they reported that patients with higher levels of c-erbB-2 overexpression had statistically significantly lower ER and PR levels than patients with lower levels of c-erbB-2 overexpression. They suggested that this finding might explain the relative resistance of c-erbB-2– positive, hormone receptor–positive tumors to hormone therapy. Given the small number of retrospective studies offering data relevant to this question, we strictly reproduced the methodology of Konecny et al. (2) in a retrospective series of 488 patients with primary breast cancer and a median follow-up of 10 years for whom c-erbB-2, ER, and PR expression had been measured by quantitative biochemical methods, allowing them to be analyzed as continuous variables. The patients’ characteristics have been published elsewhere (3). For this analysis, 101 (20.7%) of the 488 patients were considered to be c-erbB-2–positive (protein levels above 350 IU/mg protein), providing separation of patients with regard to diseasefree survival (P .002) and overall survival (P<.001). This c-erbB-2 positivity frequency is in the range of published values (2,4). Our results were as follows. First, among patients with c-erbB-2–overexpressing tumors (n 101), we found a negative correlation between c-erbB-2 and ER and PR levels (ER: r –0.41, P<.001; PR: r –0.24, P .01). Second, patients with c-erbB-2–positive tumors had statistically significantly lower absolute ER and PR levels than patients whose tumors did not overexpress c-erbB-2 (Table 1). Third, when we divided the 101 patients with c-erbB-2– positive tumors into two subgroups of approximately equal size, the median ER level was statistically significantly lower in the 52 patients with higher c-erbB-2 overexpression than in the 49 patients with weaker c-erbB-2 overexpression. Fourth, when we restricted this analysis to patients with hormone receptor–positive tumors (Table 1), those with higher c-erbB-2 overexpression had a lower median ER level than those with lower c-erbB-2 overexpression. Differences in PR levels were not statistically significant. Thus, by applying the methodology of Konecny et al. retrospectively to an independent population, we confirmed their results, i.e., the higher the level of c-erbB-2 overexpression, the lower the ER level, both in the overall population and in the subset of patients with hormone receptor–positive tumors. Because the response to endocrine therapy depends on ER and PR levels, not only on arbitrarily defined ER and PR status (positive versus negative), the lower ER and PR expression in c-erbB-2–positive/ ER-positive tumors could explain the failure of this treatment in such patients. Indeed, there is compelling evidence that cross-talk between ER and growth factor receptor pathways, such as those involving the EGFR/c-erbB-2 family, can alter ER function and thereby contribute to tumor growth and tamoxifen resistance (5–7). Taken together, these results emphasize the importance of considering the quantitative levels of c-erbB-2 and ER rather than using dichotomous systems.
منابع مشابه
Correlation of Hormone Receptor Expression with Histologic Parameters in Benign and Malignant Breast Tumors
Background and Objective: Breast cancer is the commonest cancer of Indian women. Estrogen and Progesterone expression is seen in benign breast lesions and in breast carcinoma associated with good prognostic parameters and it correlates well with response to hormone therapy. Although a lot of studies have been conducted in the past on hormone receptor expression in breast cancer and few have cor...
متن کاملRole of Cyclooxygenese-2 (COX-2) Expression in Breast Cancer Differentiation and Its Relationship with Hormone Receptors Status
Background and Objectives: Cyclooxygenese-2 (COX-2) expression in breast cancer and its correlation with tumor prognosis is unclear. We investigated the incidence of COX-2 expression in patients and assessed interactions between COX-2 and clinical features of cancer and expression of HER2/neu, estrogen receptor (ER), and progesterone receptor (PR). Methods: COX-2 expression was investigated by...
متن کاملQuantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
BACKGROUND HER-2/neu, which encodes a receptor tyrosine kinase, is amplified and overexpressed in 20%-25% of human breast cancers. Such tumors are often resistant to hormone therapy. Despite a general inverse association between HER-2/neu amplification/overexpression and estrogen receptor (ER) and/or progesterone receptor (PR) expression, a fraction of patients are both HER-2/neu- and hormone r...
متن کاملRelation between Estrogen and Progesterone Receptor Status with p53, Ki67 and Her-2 Markers in Patients with Breast Cancer
Background: Breast cancer is the most common cancer in women, containing approximately one third of all illnesses in women. Assessment of molecular markers is valuable in predicting the outcome of disease and decision making for optimal treatment. The purpose of this study was to determine the relationship between estrogen and progesterone receptors with Her-2, Ki67, P53, and clinicopathologica...
متن کاملAssociation between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.
AIMS To investigate the association between tumour characteristics and HER-2/neu by immunohistochemistry in primary operable breast cancer. METHODS The association between HER-2/neu and other clinicopathological factors was evaluated in 1362 consecutive patients with primary breast cancer treated between 2000 and July 2003 in one centre. Microscopic tumour size, tumour grade, lymph node statu...
متن کاملSteroid hormone receptors, MIB-1, p53, and c-erb-B2 expression on breast cancer: Comparison of immunohistochemistry on cell block and fine needle aspiration and tissue sample, in northwest Iran
Background: Fine-needle aspiration of breast cancer often provides moderate cellular material that is representative of the tumors. These samples can be used not only for cytological diagnosis but also to obtain information on the prognosis and likely response to therapy by using immunohistochemical staining studies. Methods: We assessed the degree of correlation between prognostic biologic ma...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Journal of the National Cancer Institute
دوره 95 18 شماره
صفحات -
تاریخ انتشار 2003